ASENAPINE MALEATE Drug Patent Profile

When do Asenapine Maleate patents expire, and when can generic versions of Asenapine Maleate launch?

Asenapine Maleate is a drug marketed by Alembic, Breckenridge, and Sigmapharm Labs Llc. and is included in three NDAs.

The generic ingredient in ASENAPINE MALEATE is asenapine maleate. There are twelve drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the asenapine maleate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Asenapine Maleate

A generic version of ASENAPINE MALEATE was approved as asenapine maleate by ALEMBIC on December 10^th, 2020.

Summary for ASENAPINE MALEATE

US Patents:	0
Applicants:	3
NDAs:	3
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ASENAPINE MALEATE

Paragraph IV (Patent) Challenges for ASENAPINE MALEATE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
SAPHRIS	Sublingual Tablets	asenapine maleate	2.5 mg	022117	1	2017-07-27
SAPHRIS	Sublingual Tablets	asenapine maleate	5 mg and 10 mg	022117	4	2013-08-13

US Patents and Regulatory Information for ASENAPINE MALEATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Alembic	ASENAPINE MALEATE	asenapine maleate	TABLET;SUBLINGUAL	206098-003	Jul 19, 2021	AB	RX	No	No
Sigmapharm Labs Llc	ASENAPINE MALEATE	asenapine maleate	TABLET;SUBLINGUAL	206107-001	Dec 10, 2020	AB	RX	No	No
Breckenridge	ASENAPINE MALEATE	asenapine maleate	TABLET;SUBLINGUAL	205960-001	Dec 10, 2020	AB	RX	No	No
Sigmapharm Labs Llc	ASENAPINE MALEATE	asenapine maleate	TABLET;SUBLINGUAL	206107-002	Dec 10, 2020	AB	RX	No	No
Alembic	ASENAPINE MALEATE	asenapine maleate	TABLET;SUBLINGUAL	206098-001	Dec 10, 2020	AB	RX	No	No
Alembic	ASENAPINE MALEATE	asenapine maleate	TABLET;SUBLINGUAL	206098-002	Dec 10, 2020	AB	RX	No	No
Breckenridge	ASENAPINE MALEATE	asenapine maleate	TABLET;SUBLINGUAL	205960-002	Dec 10, 2020	AB	RX	No	No

Asenapine Maleate Investment Scenario and Fundamentals Analysis

Last updated: February 20, 2026

What Is Asenapine Maleate?

Asenapine maleate is an atypical antipsychotic primarily approved for treating schizophrenia and bipolar disorder. It is marketed under brands such as Saphris (US) and Sycrest (Europe). The drug acts as a potent antagonist at dopamine D2 and serotonin 5-HT2A receptors, contributing to its efficacy in managing psychotic symptoms and mood stabilization.

Market Overview and Growth Drivers

The global schizophrenia drug market was valued at approximately USD 7 billion in 2021 and is expected to grow at a compound annual growth rate (CAGR) of 4.5% from 2022 to 2029[1]. The bipolar disorder segment contributes an additional USD 2.5 billion, with a CAGR of 4.8% over the same period.

Key drivers include:

• Increasing prevalence of schizophrenia and bipolar disorder.
• Growing awareness and diagnosis rates.
• Expanded indications and off-label usage.
• Enhanced formulations improving patient adherence.

Regulatory Status and Approvals

Asenapine maleate received FDA approval in 2009 for schizophrenia and in 2015 for bipolar disorder. It holds marketing authorization in multiple regions, including Europe, Asia, and Latin America. The drug's approval timeline and indications vary by jurisdiction, impacting potential market penetration.

Patent Landscape and Generic Competition

The original patent for Saphris expired in 2020 in the US, opening opportunities for generic manufacturers. Key patent expiry timelines:

Region	Original Patent Expiry	Subsequent Patents/Market Exclusivity	Generic Entry Timeline
US	2020	Data exclusivity until 2022	2020 onward
Europe	2022	Patent extensions to 2024	2022 onward

The presence of generic products reduces pricing and margins, influencing revenue streams. Proprietary formulations or delivery methods under patent can extend exclusivity.

Commercial Players and Market Share

Major pharmaceutical companies developing or marketing asenapine include:

• Sunovion Pharmaceuticals: Original developer of Saphris, holding significant market share in the US.
• Teva Pharmaceuticals: Offers generic asenapine.
• Other generic manufacturers: Entered global markets post-patent expiry.

Sunovion's revenue from Saphris was approximately USD 500 million in 2018; revenues declined post-patent expiry but remain significant due to ongoing brand loyalty and formulations.

R&D Pipeline and Future Opportunities

Current R&D efforts focus on:

• Developing long-acting injectables for improved adherence.
• Oral dissolvable formulations.
• Investigating expanded indications (e.g., treatment-resistant depression, irritability in autism).

No late-stage pipeline compounds under development specifically for asenapine are publicly reported, limiting near-term pipeline prospects.

Price and Reimbursement Dynamics

Pricing varies substantially across regions:

• US: USD 25–USD 40 per tablet (for branded Saphris).
• Europe: EUR 20–EUR 35 per tablet.
• Generics: 30–50% lower than brand prices.

Reimbursement policies affect market access. In the US, Medicaid and Medicare Part D cover significant portions, influencing sales volume.

Financial Outlook and Investment Risks

Revenue Risks

• Patent expiration diminishing revenue.
• Increasing generic competition.
• Price erosion pressures.

Market Expansion Risks

• Regulatory delays in new indications.
• Market acceptance of formulations.
• Off-label usage impacting legal and reimbursement environments.

Development and Regulatory Risks

• Unsuccessful R&D efforts for derivatives or extended-release forms.
• Adverse regulatory decisions on safety or efficacy.

Competitive Landscape

• Other atypical antipsychotics (e.g., risperidone, aripiprazole) dominate market share.
• New drugs with better safety profiles or efficacy may erode asenapine's market position.

Investment Considerations

Investment value hinges on:

• Intellectual property rights: patent grants extending to 2024-2026 in key markets.
• Market penetration strategies: focus on differentiated formulations.
• Cost structure and pricing power amid generic competition.
• R&D pipeline success, especially in formulation improvements.

Key Takeaways

• Asenapine maleate remains a relevant treatment option with stable demand.
• Patent expiry in major markets introduces revenue headwinds.
• Generics significantly impact pricing and market share.
• R&D efforts are limited but may focus on formulations to extend lifecycle.
• Market growth is driven by increasing mental health disorder prevalence, but competitive pressures increase risks.

FAQs

1. Does asenapine maleate have patent protection?
Patents for the original formulation expired in the US in 2020, with some extensions until 2024 in Europe. No new patents on formulations are publicly reported.

2. What are the main competitors?
Main competitors are other atypical antipsychotics such as risperidone, olanzapine, quetiapine, and aripiprazole.

3. How does generic entry impact revenues?
Generic entry typically reduces pricing by 30-50% and erodes brand market share, impacting revenue significantly.

4. Are there new formulations under development?
No publicly announced late-stage formulations specifically for asenapine; ongoing research focuses on long-acting injectable and dissolvable forms.

5. What is the outlook for future growth?
Growth will depend on market share retained post-patent expiry, success in formulation innovation, and expansion into new indications.

References

[1] Markets and Markets. (2022). Global schizophrenia drugs market.